A randomized, blinded, phase IIb trial of telbivudine (LdT) versus the combination of telbivudine and valtorcitabine (Val-LdC) in patients with chronic hepatitis B.
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2017
At a glance
- Drugs Valtorcitabine (Primary) ; Telbivudine
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Idenix Pharmaceuticals
- 15 Dec 2009 Actual end date (1 May 2007) added as reported by ClinicalTrials.gov record.
- 15 Dec 2009 Actual initiation date (1 May 2005) and planned number of patients (130) added as reported by ClinicalTrials.gov record.
- 15 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.